MORF-088 / Schrodinger, Eli Lilly - LARVOL DELTA

Inhibition of integrin αvβ8 in combination with low dose radiation induces antitumor effect in advanced immune checkpoint blockade refractory tumor model (SITC 2021) - "The anti-tumor effect was driven by enhancement of adaptive immunity, improvement of DC function and reduced tumor tolerance. These data provide evidence that αvβ8 inhibition enhances RIT and may be effective against ICB refractory tumors."

Checkpoint inhibition • Combination therapy • IO biomarker • Preclinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • PD-1 • TGFB1

Morphic Presents Preclinical Data from αvβ8 Integrin Program at the SITC Annual Meeting (GlobeNewswire) - "αvβ8 inhibition demonstrates efficacy in a cancer model refractory to radiation and checkpoint inhibition. Data provide increased rationale to explore integrin inhibition as a component in combination immunotherapy to drive anti-tumor response via TGFβ pathway."

Preclinical • Oncology • Solid Tumor

[VIRTUAL] Inhibition of integrin αvβ8 enhances immune checkpoint induced anti-tumor immunity by acting across immunologic synapse in syngeneic models of breast cancer (AACR 2021) - "Efficacy was confirmed in PyMT breast cancer model.Conclusions An αvβ8 inhibitor in combination with anti-PD-1 showed efficacy in syngeneic mouse models, supported by increased T cell infiltrates and evidence of reduced tumor tolerance. These results show that an orally administered αvβ8 targeted inhibitor is a potent modulator of anti-tumor immune response acting across the immunologic synapse, and is a promising therapeutic approach to ICB refractory tumors."

IO biomarker • Breast Cancer • Oncology • Solid Tumor • CCL2 • CCL22 • CCR7 • CD40 • CD69 • CD8 • CTLA4 • IFNG • IL10 • TGFB1 • TIGIT

Morphic Therapeutic Presents Preclinical Data from αvβ8 Integrin Program at American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - “Morphic Therapeutic…announced the presentation of the first preclinical data from its αvβ8 integrin program at the 2021 American Association for Cancer Research (AACR) Annual Virtual Meeting. These preclinical data show that an orally administered αvβ8 integrin inhibitor is a potent modulator of anti-tumor immune response in checkpoint-inhibitor resistant tumors and support development of this new therapeutic approach. αvβ8 is known to mediate the activation of tumor growth factor beta (TGFβ1/3). Morphic is developing oral small molecule inhibitors of the αvβ8 integrin which is expressed on cell types central to immune response and is a major contributor to tolerance and suppression of anti-tumor immunity.”

Preclinical • Breast Cancer • Oncology